FDA Inspection 922741 — Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany — FEI 2211084

The FDA completed an inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on April 24, 2015 in Whippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 24, 2015
Fiscal Year
2015
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Whippany, NJ (United States)